BridgeBio Pharma Inc. (NASDAQ:BBIO) traded with an addition of $0.07 to $28.66 on Thursday, an upside of 0.26 percent. An average of 1,517,071 shares of common stock have been traded in the last five days. There was a gain of $0.19 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 1,893,358 shares traded, while the 50-day average volume stands at 3,516,613.
BBIO stock has decreased by -11.56% in the last month. The company shares reached their 1-month lowest point of $27.58 on 08/22/23. With the stock rallying to its 52-week high on 07/18/23, shares of the company touched a low of $6.64 and a high of $36.36 in 52 weeks. It has reached a new high 21 times so far this year and achieved 276.17% or $20.98 in price. In spite of this, the price is down -21.17% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
BBIO stock investors should be aware that BridgeBio Pharma Inc. (BBIO) stock had its last reported insider trading activity 7 days ago on Aug 17. In this transaction, the insider spent $1,473,784. Secretary, Treasurer & CFO, STEPHENSON BRIAN C, disposed of 22,683 shares at a price of $28.59 on Aug 17. The insider now owns more than $648,455 worth of shares. Prior to that, 10% Owner VIKING GLOBAL INVESTORS LP went on to Sale 1,500,000 shares at $35.00 each on Jul 18. An amount of $52,500,000 was transacted.
Valuation Metrics
BridgeBio Pharma Inc. (BBIOstock’s beta is 0.99. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 808.22.
Financial Health
The quick ratio of BridgeBio Pharma Inc. for the three months ended June 29 was 3.90, and the current ratio was 3.90, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at $74.21 million compared to revenue of $77.65 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, BridgeBio Pharma Inc.’s return on assets was -92.40%.
Earnings Surprise
For the three-month period that ended June 29, BridgeBio Pharma Inc. had $440.5 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$157.9 million in the quarter, while revenues were grew 93.76%. The analyst consensus anticipated BridgeBio Pharma Inc.’s latest quarter earnings to come in at -$0.83 per share, but it turned out to be -$0.98, a -18.10% surprise. For the quarter, EBITDA amounted to -$144.46 million. Shareholders own equity worth $162.47 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at BridgeBio Pharma Inc. (BBIO) price momentum. RSI 9-day as of the close on 23 August was 39.47%, suggesting the stock is Neutral, with historical volatility in this time frame at 31.59%.
As of today, BBIO’s price is $28.57 +0.67% or $0.19 from its 5-day moving average. BBIO is currently trading -10.99% lower than its 20-day SMA and +72.50% higher than its 100-day SMA. However, the stock’s current price level is +70.75% above the SMA50 and +190.65% above the SMA200.
The stochastic %K and %D were 17.80% and 15.33%, respectively, and the average true range (ATR) was 1.42. With the 14-day stochastic at 20.52% and the average true range at 1.54, the RSI (14) stands at 48.03%. The stock has reached -0.72 on the 9-day MACD Oscillator while the 14-day reading was at -1.59.
Analyst Ratings
Jefferies downgraded BridgeBio Pharma Inc. (NASDAQ: BBIO) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for BridgeBio Pharma Inc. (BBIO) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell BBIO, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 9 others rate it as a “buy”.
What is BBIO’s price target for the next 12 months?
Analysts predict a range of price targets between $33.00 and $60.00, with a median target of $48.00. Taking a look at these predictions, the average price target given by analysts for BridgeBio Pharma Inc. (BBIO) stock is $46.00.
